文献速递膀胱癌与上尿路尿路上皮癌

肉瘤样分化患者膀胱切除术后的病理与肿瘤学结局

Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
PubMed 文献 · BJU Int · 2021-05-24

该回顾性研究纳入1995–2018年Memorial Sloan Kettering癌症中心接受膀胱切除术的尿路上皮癌患者,比较肉瘤样分化与无变异组织学患者的病理缓解和生存结局。肉瘤样分化组分期更高且更常接受新辅助化疗,但两组的病理部分缓解和完全缓解率无差异;校正分期等因素后,肉瘤样分化与更差的复发-free、疾病特异和总生存独立相关。

要点

  • 肉瘤样分化患者分期更高(94%≥T2 vs 62%),更常接受新辅助化疗(29% vs 18%)。
  • 经尿道切除标本中肉瘤样分化与纯尿路上皮癌的病理缓解率无显著差异。
  • 校正分期等因素后,肉瘤样分化与更差的复发-free、疾病特异和总生存独立相关。

核心结论

  • 肉瘤样分化与更高的就诊分期和独立更差的生存相关。
  • 若初始切除即检出肉瘤样分化,其病理缓解率与纯尿路上皮癌相似,且接受新辅助化疗者生存更好,故新辅助化疗似有指征。

研究设计与样本

  • 回顾性队列研究,纳入1995–2018年Memorial Sloan Kettering癌症中心接受膀胱切除术的尿路上皮癌患者。
  • 肉瘤样分化组131例,无变异组织学组1722例;其中肉瘤样分化组25例、无变异组织学组313例接受新辅助化疗。

主要发现

  • 肉瘤样分化组共识肿瘤分期更高(94%≥T2 vs 62%,P<0.001),接受新辅助化疗比例更高(29% vs 18%,P=0.003)。
  • 经尿道切除标本中,肉瘤样分化与纯尿路上皮癌的病理部分缓解率(24% vs 31%)和完全缓解率(20% vs 24%)无显著差异(P=0.6)。
  • 肉瘤样分化组中,接受新辅助化疗者5年复发-free生存55%(95%CI 41–74),仅行膀胱切除术者40%(95%CI 31–52),P=0.1。
  • 校正分期、淋巴结受累、切缘状态和新辅助化疗后,肉瘤样分化与更差的复发-free生存(HR 1.82,95%CI 1.39–2.39)、疾病特异生存(HR 1.66,95%CI 1.23–2.22)和总生存(HR 1.37,95%CI 1.06–1.78)相关。

关键数值与推荐

  • 部分缓解定义为从≥cT2降至≤pT1N0,完全缓解定义为pT0N0。

临床怎么用

  • 对于经尿道切除标本检出肉瘤样分化的尿路上皮癌患者,可考虑给予新辅助化疗。
  • 肉瘤样分化患者预后较差,需关注其他导致不良结局的因素并进一步研究。

局限性

  • 回顾性单中心研究设计。
  • 肉瘤样分化组接受新辅助化疗的样本量较小(25例)。
  • 新辅助化疗亚组生存比较的P值为0.1,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether urothelial carcinoma (UC) with sarcomatoid differentiation is associated with a lower pathological response rate to neoadjuvant chemotherapy (NAC) and worse oncological outcomes compared to UC without variant histology among patients undergoing radical cystectomy. PATIENTS AND METHODS: Patients with UC undergoing cystectomy from 1995 to 2018 at the Memorial Sloan Kettering Cancer Centre were identified. Patients with sarcomatoid differentiation at transurethral resection (TUR) or cystectomy, and patients without variant histology were selected. Downstaging from ≥cT2 to ≤pT1N0 defined partial response and pT0N0 defined complete response. Recurrence-free, cancer-specific and overall survival were modelled. RESULTS: We identified 131 patients with sarcomatoid differentiation and 1722 patients without variant histology, of whom 25 with sarcomatoid histology on biopsy and 313 without variant histology received NAC. Those with sarcomatoid differentiation presented with higher consensus tumour stage (94% ≥T2 vs 62%; P < 0.001) and were, therefore, more likely to receive NAC (29% vs 18%; P = 0.003). We found no evidence to support a difference in partial (24% vs 31%) or complete (20% vs 24%) response between patients with sarcomatoid histology and those with pure UC at TUR (P = 0.6). Among patients with sarcomatoid differentiation, 5-year recurrence-free survival was 55% (95% confidence interval [CI] 41-74) among patients receiving NAC and 40% (95% CI 31-52) among patients undergoing cystectomy alone (P = 0.1). Adjusting for stage, nodal involvement, margin status and receipt of NAC, sarcomatoid differentiation was associated with worse recurrence-free (hazard ratio [HR] 1.82, 95% CI 1.39-2.39), disease-specific (HR 1.66, 95% CI 1.23-2.22), and overall survival (HR 1.37, 95% CI 1.06-1.78). CONCLUSIONS: Sarcomatoid differentiation was associated with higher stage at presentation and independently associated with worse survival. Given similar pathological response rates if sarcomatoid differentiation is detected at initial resection, and greater survival among patients receiving NAC, treatment with NAC appears warranted. Other drivers of the poor outcomes of this histology must be investigated.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Almassi N, Vertosick EA, Sjoberg DD, et al. Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU Int. 2021. PMID: 33866683. doi:10.1111/bju.15428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。